Sampling Human Company Profile

Background

Sampling Human is a biotechnology company dedicated to revolutionizing health measurement by making single-cell analysis accessible and actionable. Founded by a team of engineers, scientists, and entrepreneurs, the company has developed the world's first universal single-cell platform, a culmination of nearly a decade of research in synthetic biology. This platform aims to provide precise, scalable, and data-rich solutions for clinical diagnostics and therapeutic development.

Key Strategic Focus

Sampling Human's strategic objectives include:

Pre-Symptomatic Screening: Enabling early detection of diseases at the cellular level.

Personalized Medicine: Facilitating tailored therapeutic approaches based on individual cellular profiles.

Drug Discovery: Accelerating the identification and development of novel therapeutics through advanced cellular analysis.

Basic Science: Advancing fundamental understanding of cellular behaviors and interactions.

The company's proprietary technologies leverage synthetic biology to engineer living cells capable of analyzing other cells, thereby enhancing diagnostic precision and efficiency.

Financials and Funding

As of April 2022, Sampling Human has raised a total of $3.7 million in seed funding. The most recent funding round, completed on April 13, 2022, secured $2 million and was led by i&i Biotech Fund, with participation from Longevitytech.fund and Formic Ventures. The capital is intended to advance research and development, expand the team, and enhance business development efforts.

Pipeline Development

Sampling Human offers a range of biocytometry kits designed for various applications:

Cell Enumeration: Kits for counting specific cell types with a streamlined workflow requiring minimal equipment and hands-on time.

Cell-Specific Apoptosis: Tools to enumerate apoptotic cells using luminescent readouts, allowing precise targeting of apoptotic subpopulations.

CAR T-Cell Enumeration: Universal detection kits for functional CAR T-cells, offering sensitivity that surpasses traditional methods.

Single-Cell Omics: Kits for targeted omics readouts, eliminating costly steps like FACS and enabling direct sequencing of cells of interest.

Technological Platform and Innovation

Sampling Human's innovation is anchored in its proprietary "Diagnostics On Target" (DOT) platform, which utilizes genetically engineered cells to analyze other cells within their environment. This approach offers:

Proprietary Technologies: Engineered yeast cells capable of detecting and classifying specific living cells, such as cancer cells, within complex samples.

Significant Scientific Methods: The DOT platform translates vast amounts of single-cell data into actionable clinical insights, enhancing early disease detection and treatment monitoring.

Leadership Team

Daniel Georgiev, Ph.D.: Co-Founder and CEO with over 20 years of experience in deep tech organizations, specializing in systems engineering, synthetic biology, and machine learning.

Hynek Kasl: Co-Founder and Director of Engineering, overseeing the development and implementation of the company's technological solutions.

Martin Cienciala: Co-Founder and Director of Product Development, responsible for guiding the product lifecycle from conception to market.

Christopher Kan: Director of Business Development, leading strategic partnerships and market expansion initiatives.

Sherry Heldens: Director of Operations, managing the company's operational strategies and processes.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within Sampling Human's leadership team.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in single-cell analysis, is experiencing significant growth due to increasing demand for personalized medicine and early disease detection. Advancements in synthetic biology and data analytics are driving innovation, with a focus on developing more precise and scalable diagnostic tools.

Competitor Analysis

Key competitors in the single-cell analysis market include companies like 10x Genomics and Fluidigm Corporation, both specializing in high-throughput single-cell technologies. These companies focus on providing comprehensive solutions for single-cell genomics, transcriptomics, and proteomics, catering to research institutions and pharmaceutical companies.

Strategic Collaborations and Partnerships

Sampling Human has established significant collaborations to enhance its technological capabilities and market reach:

i&i Prague: A partnership agreement signed in December 2019 to support the commercialization of living diagnostics for drug discovery and bioengineering.

BMG LABTECH: In May 2024, Sampling Human partnered with BMG LABTECH to release an application note pairing their biocytometry kits with BMG LABTECH microplate readers, enhancing the usability and performance of their products.

Operational Insights

Sampling Human operates state-of-the-art facilities in San Francisco and Prague, leveraging global innovation potential. These facilities, in conjunction with a network of clinical institutions and core facilities, enable the company to engineer, discover, and validate single-cell technologies and biomarkers with unprecedented speed and depth.

Strategic Opportunities and Future Directions

Looking ahead, Sampling Human aims to expand its product offerings, enhance its technological platforms, and establish additional strategic partnerships to strengthen its market position. The company's focus on making single-cell analysis more accessible positions it to play a pivotal role in advancing personalized medicine and improving patient outcomes.